The investment research and advisory company, Edison Investment Research, has released an independent and detailed analyst report into T-cell cancer therapies, highlighting the potential and limitations of current CAR-T approaches for most tumour types.
Report
This free report is a result of the rapidly advancing landscape within this therapeutic area — Novartis’ Kymriah was recently approved by the FDA and a second CAR-T cell therapy from Kite Pharma predicted to be approved soon. It provides analysis on current events in CAR-T and the available technologies, solutions and predictions for the future of these therapies.